Malignancies associated with systemic sclerosis

Autoimmunity Reviews

Volumn 11, Issue 12, 2012, Pages 852-855

  Szekanecz, Éva ^a   Szamosi, Szilvia ^a   Horváth, Ágnes ^a   Németh, Ágnes ^a   Juhász, Balázs ^a   Szántó, János ^a   Szücs, Gabriella ^a   Szekanecz, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Immunosuppression; Secondary malignancies; Systemic sclerosis; Tumor development

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BREAST CANCER; BRONCHUS CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CARCINOGENICITY; COMORBIDITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE REGISTRY; ESOPHAGUS CANCER; FOLLOW UP; HUMAN; LEIOMYOSARCOMA; LYMPHOMA; NONHODGKIN LYMPHOMA; REVIEW; RHEUMATIC DISEASE; SCLERODERMA; SKIN CANCER; SOLID TUMOR; SURVIVAL RATE; SYSTEMIC SCLEROSIS; UTERINE CERVIX CANCER;

AGED; ANIMALS; COMORBIDITY; HUMANS; HUNGARY; INCIDENCE; MIDDLE AGED; NEOPLASMS; REGISTRIES; RISK; SCLERODERMA, SYSTEMIC;

EID: 84866535017     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.02.021     Document Type: Review

References (36)

1. Szekanecz E., Andras C., Sandor Z., Antal-Szalmas P., Szanto J., Tamasi L., et al. Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmun Rev 2006, 6(1):42-47.
2. Kiss E., Kovacs L., Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev 2010, 9(4):195-199.
3. Kovacs L., Szodoray P., Kiss E. Secondary tumours in Sjogren's syndrome. Autoimmun Rev 2010, 9(4):203-206.
4. Szekanecz Z., Szekanecz E., Bako G., Shoenfeld Y. Malignancies in autoimmune rheumatic diseases-a mini-review. Gerontology 2011, 57(1):3-10.
5. Czirjak L., Kumanovics G., Varju C., Nagy Z., Pakozdi A., Szekanecz Z., et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008, 67(1):59-63.
6. Bernatsky S., Ramsey-Goldman R., Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol 2006, 18(2):129-134.
7. Chakravarty E., Genovese M.C. Rheumatic syndromes associated with malignancy. Curr Opin Rheumatol 2003, 15(1):35-43.
8. Askling J., Fored C.M., Baecklund E., Brandt L., Backlin C., Ekbom A., et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64(10):1414-1420.
9. Abu-Shakra M., Guillemin F., Lee P. Cancer in systemic sclerosis. Arthritis Rheum 1993, 36(4):460-464.
10. Szekanecz E., Szamosi S., Gergely L., Keszthelyi P., Szekanecz Z., Szucs G. Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis. Clin Rheumatol 2008, 27(9):1163-1166.
11. Wooten M. Systemic sclerosis and malignancy: a review of the literature. South Med J 2008, 101(1):59-62.
12. Derk C.T., Rasheed M., Artlett C.M., Jimenez S.A. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006, 33(6):1113-1116.
13. Roumm A.D., Medsger T.A. Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum 1985, 28(12):1336-1340.
14. Askling J., Baecklund E., Granath F., Geborek P., Fored M., Backlin C., et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009, 68(5):648-653.
15. Asten P., Barrett J., Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999, 26(8):1705-1714.
16. Lu T.Y., Hill C.L., Pontifex E.K., Roberts-Thomson P.J. Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study. Rheumatol Int 2008, 28(9):895-899.
17. Pontifex E.K., Hill C.L., Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 2007, 66(4):551-553.
18. Hill C.L., Nguyen A.M., Roder D., Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003, 62(8):728-731.
19. Chatterjee S., Dombi G.W., Severson R.K., Mayes M.D. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005, 52(8):2415-2424.
20. Kojima M., Itoh H., Shimizu K., Saruki N., Murayama K., Higuchi K., et al. Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases. Int J Surg Pathol 2006, 14(1):43-48.
21. Launay D., Le Berre R., Hatron P.Y., Peyrat J.P., Hachulla E., Devulder B., et al. Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clin Rheumatol 2004, 23(6):516-522.
22. Derk C.T., Conway R.T., Jimenez S.A. Primary B-cell lymphoma of the tongue in a patient with systemic sclerosis. Oral Oncol 2004, 40(1):103-106.
23. Arnaud L., Chryssostalis A., Terris B., Pavy S., Chaussade S., Kahan A., et al. Systemic sclerosis and gastric MALT lymphoma. Joint Bone Spine 2006, 73(1):105-108.
24. Shah A.A., Rosen A. Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr Opin Rheumatol 2011, 23(6):530-535.
25. Racanelli V., Prete M., Minoia C., Favoino E., Perosa F. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 2008, 7(5):352-358.
26. Bernatsky S., Clarke A.E., Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008, 168(4):378-381.
27. Kinlen L.J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985, 78(1A):44-49.
28. Moder K.G., Tefferi A., Cohen M.D., Menke D.M., Luthra H.S. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 1995, 99(3):276-281.
29. Isik M., Turker B., Agit A., Calguneri M. Systemic sclerosis and malignancies after cyclophosphamide therapy: a single center experience. Rheumatol Int 2012, 32:1111.
30. Szekanecz Z., Szanto S., Szabo Z., Vancsa A., Szamosi S., Bodnar N., et al. Biologics-beyond the joints. Autoimmun Rev 2010, 9(12):820-824.
31. Salliot C., van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009, 68(7):1100-1104.
32. Silver R.M., Warrick J.H., Kinsella M.B., Staudt L.S., Baumann M.H., Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993, 20(5):838-844.
33. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23(5):581-590.
34. Tarr T., Gyorfy B., Szekanecz E., Bhattoa H.P., Zeher M., Szegedi G., et al. Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: results from a single center. Ann N Y Acad Sci 2007, 1108:76-82.
35. Szabolcs O., Kasler M. Trends in cancer mortality and morbidity in Hungarian and international statistics. Hung Oncol 2005, 49:99-107.
36. Szekanecz E., Szekanecz Z., Kiss E., Keszthelyi P., Szántó J., Szücs G. Secondary malignancies in systemic sclerosis. Hung Rheumatol 2009, 50:4-9.